The Impact of Skin and Soft Tissue Infections (SSTIs)
Skin and soft tissue infections (SSTIs) represent a formidable challenge in clinical practice, ranging from superficial infections to life-threatening necrotizing processes. Epidemiological data from England indicates that the overall prevalence of healthcare-associated infections (HCAIs) is approximately 6.4%, with surgical site infections (SSIs) constituting the third most common category at 15.7%.
SSIs are particularly resource-intensive, complicating between 10% and 20% of surgical operations depending on the specialty and surveillance comprehensiveness. These infections are associated with significant morbidity; over a third of postoperative deaths are linked to SSIs. Beyond mortality, the economic burden is substantial, often requiring extended inpatient treatment and additional procedures costing thousands of pounds per case.
Summary of Current Trends: The incidence of SSI after surgery is not falling. Based on this review of published trials and evidence-based systematic reviews, some advances might be included into these care bundles. More research is needed together with improved compliance with care bundles.
Categorizing the Infection: Purulent vs. Nonpurulent Presentations
In the current era of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA), differentiating between purulent and nonpurulent presentations is the cornerstone of effective empirical antimicrobial selection.
Comparison of Cellulitis Classifications
| Feature | Purulent Cellulitis | Nonpurulent Cellulitis |
| Clinical Presentation | Characterized by purulent drainage or exudate; often lacks a drainable abscess. | Characterized by erythema and edema; absence of purulence, exudate, or associated abscess. |
| Primary Pathogens | Frequently CA-MRSA. | Predominantly \beta-hemolytic streptococci. |
| Management Goal | Primary focus on Incision and Drainage (I&D). | Primary focus on antimicrobial eradication of streptococci. |
For outpatients where CA-MRSA is suspected, empirical oral antibiotic options include:
- Clindamycin: (Note: A D-zone test must be performed on erythromycin-resistant, clindamycin-susceptible isolates to detect inducible resistance before use).
- Trimethoprim-sulfamethoxazole (TMP-SMX)
- Tetracyclines (Doxycycline or Minocycline)
- Linezolid
Diagnostic Challenges: When “Cellulitis” is a Mask for Necrotizing Fasciitis
Necrotizing Fasciitis (NF) is a surgical emergency characterized by rapid tissue destruction, advancing at rates of up to one inch per hour. Because early clinical findings often mimic simple cellulitis, clinicians must maintain a high index of suspicion.
Stages of Progression
- Early: Patients present with localized erythema and flu-like symptoms. The hallmark diagnostic clue is pain disproportionate to the visible clinical findings.
- Advanced: Characterized by systemic toxicity, including fever, tachycardia, and hypotension. Bullae (large blisters) may appear with clear, foul-smelling, or hemorrhagic drainage.
- Critical: Rapid descent into sepsis, multisystem organ failure, and coma.
Surgical Confirmation
The “finger test” remains the definitive bedside diagnostic maneuver. During surgical exploration, the surgeon inserts an index finger into the fascial layers; if the fascia and dermis separate easily with minimal resistance, the test is positive for NF.
Preexisting Conditions for High Risk
The following comorbidities significantly increase the risk of severe outcomes and require aggressive monitoring:
- Alcoholism
- Chronic renal or liver disease
- Compromised immune systems
- Diabetes mellitus
- IV drug abuse
- Obesity
- Peripheral vascular disease
- Smoking
Anatomical and Pathological Red Flags
While standard cellulitis is generally confined to the superficial dermis, NF involves a rapid, “flesh-eating” progression through the deep subcutaneous tissue and fascia.
Clinical Signs of Progression:
- Bullae and Crepitus: Large blisters or a “woody,” crunchy sensation upon palpation (crepitus) indicates the presence of subcutaneous gas, a hallmark of anaerobic activity.
- Systemic Toxicity: Tachycardia and hypotension are markers of a significant systemic tissue bioburden and impending shock.
- The Ominous Sign: As the infection transitions into the Advanced and Critical stages, a sudden lessening of pain or localized anesthesia occurs. This is a grave marker of deep nerve destruction and tissue death.
Identifying Atypical Causes: Buruli Ulcer and Leprosy
When lesions fail to respond to standard \beta-lactam or MRSA-active therapies, clinicians must investigate atypical mycobacterial causes.
Buruli Ulcer (Mycobacterium ulcerans)
This is a necrotizing infection driven by the mycolactone toxin, which causes massive tissue necrosis and immunosuppression. It typically presents as a painless nodule or plaque that eventually breaks down into a characteristic painless ulcer with undermined edges.
Leprosy (Mycobacterium leprae)
Leprosy is a chronic communicable disease primarily affecting the skin and peripheral nerves. The pathognomonic sign is a skin patch (pale, reddish, or copper-colored) with a definite loss of sensation to heat, touch, or pain. These patches typically do not itch or hurt. Clinical Trap: Clinicians should note that reddish or skin-colored nodules may manifest without immediate sensation loss, representing a critical diagnostic pitfall.
Checklist for Atypical Suspicion
- [ ] Is there a definite loss of sensation within a skin patch? (Suspect Leprosy)
- [ ] Are there reddish/skin-colored nodules present, even if sensation is intact? (Rule out Leprosy)
- [ ] Is the ulcer painless but characterized by significantly undermined edges? (Suspect Buruli Ulcer)
- [ ] Does the skin patch fail to itch? (Suspect Leprosy)
- [ ] Is there a failure of clinical response to standard antibiotic protocols?
Management Protocols and Hospitalization Criteria
Conditions Requiring Antimicrobial Therapy after Incision and Drainage
While I&D is the primary treatment for abscesses, adjunctive antibiotics are required for:
- Severe or extensive disease (multiple sites).
- Rapid progression associated with cellulitis.
- Signs of systemic illness.
- Associated comorbidities or immunosuppression (e.g., DM, HIV/AIDS).
- Extremes of age (very young or elderly).
- Abscesses in areas difficult to drain (face, hands, genitalia).
- Associated septic phlebitis or lack of response to I&D alone.
Hospitalization for Complicated SSTIs (cSSTI)
Hospitalization is indicated for deeper soft-tissue infections, major abscesses, or infected ulcers and burns. Recommended intravenous (IV) options for MRSA coverage include:
- Vancomycin
- Linezolid (100% oral bioavailability; transition once stable)
- Daptomycin (Clinical Warning: Daptomycin is inhibited by pulmonary surfactant and should not be used for the treatment of non-hematogenous MRSA pneumonia).
- Telavancin
- Clindamycin
Technical Note: Vancomycin Monitoring For serious infections (e.g., NF, bacteremia), serum trough concentrations should be maintained between 15–20 \mug/mL. These troughs must be obtained at steady-state conditions, specifically prior to the fourth or fifth dose.
Conclusion: The Importance of Clinical Vigilance
The prevention of permanent disability and death hinges on rapid clinical recognition. Early intervention—whether through Multidrug Therapy (MDT) for leprosy or immediate, aggressive surgical debridement for necrotizing fasciitis—is paramount. Clinicians must remain vigilant for the subtle “red flags” of nerve destruction and the atypical presentations of mycobacterial disease to ensure optimal patient outcomes.